Tolerability of HIV integrase inhibitors

@article{Lee2012TolerabilityOH,
  title={Tolerability of HIV integrase inhibitors},
  author={Frederick J. Lee and Andrew Carr},
  journal={Current Opinion in HIV and AIDS},
  year={2012},
  volume={7},
  pages={422–428}
}
  • F. Lee, A. Carr
  • Published 1 September 2012
  • Medicine
  • Current Opinion in HIV and AIDS
Purpose of reviewThis review discusses the available safety data for three integrase strand transfer inhibitors (INSTIs) – raltegravir, elvitegravir and dolutegravir – derived from studies in both HIV-infected and HIV-uninfected cohorts. Recent findingsPhase 2 and 3 clinical trials show that all three INSTIs are well tolerated in treatment-naive and treatment-experienced patients with headache and gastrointestinal effects being the most commonly reported adverse events. Other nervous system… 
Tolerability of integrase inhibitors in a real-life setting
TLDR
Discontinuations due to any reason tended to be less common with elvitegravir, but discontinuation due to toxicity did not differ among integrase inhibitors, and neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravIR.
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
TLDR
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI), which has now been licensed to be used in different countries including the UK and is a minor substrate for CYP-450.
Raltegravir as antiretroviral therapy in HIV/AIDS
TLDR
Raltegravir, the first integrase inhibitor in the armamentarium against HIV, has been shown to be efficacious in both treatment-naïve and treatment-experienced patients when used in combination as part of nucleoside-reverse transcriptase inhibitor-containing regimens.
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection
TLDR
The dolutegravir/abacavir/lamivudine regimen is highly effective in achieving sustained suppression of HIV-1 RNA plasma concentrations and has a favorable safety profile and a low potential for drug interactions.
Elvitegravir for the treatment of HIV
TLDR
Elvitegravir offers clinicians a convenient choice for HIV-positive patients that is safe and effective for both treatment-naïve and experienced patients, as well as an option for regimen simplification in virologically suppressed patients.
Dolutegravir plus lamivudine for the treatment of HIV-1 infection
TLDR
This review is intended to provide insight about the efficacy, safety, and tolerability of a 2DR with dolutegravir plus lamivudine in naïve and treatment-experienced patients and shows that DTG+3TC is an effective and safe switch option for the treatment of experienced patients.
The place of raltegravir in the clinical management of HIV-1 infection
TLDR
The high viral potency of the drug, the excellent safety profile with a good immediate tolerability and a favorable long-term metabolic profile, have placed RAL, the first approved integrase strand transfer inhibitor, in a key position within the HIV armamentarium.
Next-Generation Integrase Inhibitors
TLDR
Dolutegravir is the most advanced second-generation integrase inhibitor, and it boasts good tolerability, once-daily dosing with no need for a pharmacological enhancer, and relatively little cross-resistance with raltegravIR.
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
TLDR
The use of integrase inhibitors in children and adolescents is summarized, the results of recent clinical trials are highlighted, and the potential for use in children is highlighted.
Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient
TLDR
This case aims to recognize rhabdomyolysis as a rare, but possible adverse effect associated with the use of Triumeq for HIV-infected patients and therefore clinicians prescribing this combination should be aware of this potential side effect and counsel their patients accordingly.
...
1
2
3
4
...

References

SHOWING 1-10 OF 54 REFERENCES
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
TLDR
Elvitegravir was well-tolerated and produced rapid virologic suppression that was durable with active background therapy that was impacted by activity of background agents.
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
  • Y. Yazdanpanah, C. Fagard, G. Chêne
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
TLDR
In patients infected with multidrug-resistant virus who have few remaining treatment options, the combination of raltegravir, etravirine, and darunavir/ritonavir is well tolerated and is associated with a rate of virologic suppression similar to that expected in treatment-naive patients.
Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results
TLDR
The HIV treatment regimen of LPV/r + RAL resulted in noninferior efficacy and comparable safety and tolerability compared with a traditional NRTI-containing regimen through 48 weeks of treatment.
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
TLDR
It is proposed that most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains and the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in theDevelopment of second- and third-generation IN inhibitors.
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
TLDR
In well-suppressed patients with multidrug-resistant HIV infection, a switch from enfuvirtide to raltegravir is generally well tolerated and has sustained antiviral efficacy when combined with a potent background regimen.
Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients
TLDR
GS-9137 demonstrated substantial short-term antiviral activity and was well tolerated as monotherapy, thus warranting further study.
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
TLDR
Using cobicistat and ritonavir as pharmacoenhancers for atazanavir and administered with emtricitabine/tenofovir df achieved comparable rates of virologic suppression and CD4 cell count increase with satisfactory safety profiles.
Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects
TLDR
Raltegravir is generally well tolerated at doses of up to 1,600 mg/day given for up to 10 days and exhibits a pharmacokinetic profile supportive of twice‐daily dosing with multiple doses of 100 mg and greater achieving trough levels >33 nM.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
TLDR
Dolutegravir demonstrated potent antiviral activity, good short-term tolerability, low pharmacokinetic variability, and a predictable pharmacokinetics/pharmacodynamics relationship, which support once-daily dosing without a pharmacokinetically booster in integrase-naive patients in future studies.
...
1
2
3
4
5
...